A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Related Experiment Video

Updated: Feb 7, 2026

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

4.3K

Yong Cheng1,2,3,4, Qingyu Meng1,2,3,4, Dandan Linghu1,2,3,4

  • 1Department of Ophthalmology, Peking University People's Hospital, Beijing, China.

Scientific Reports
|July 18, 2018
PubMed

Insights

A low dose of intravitreal conbercept (IVC) effectively treats retinopathy of prematurity (ROP) in Zone II. This treatment showed high success rates with no adverse ocular outcomes in premature infants.

Area of Science:

  • Ophthalmology
  • Neonatology
  • Pharmacology

Background:

  • Intravitreal conbercept (IVC) is used for retinopathy of prematurity (ROP).
  • Concerns exist regarding systemic VEGF reduction and potential complications in premature infants due to IVC's systemic absorption.
  • Evaluating lower IVC dosages is crucial for safety and efficacy in vulnerable populations.

Purpose of the Study:

  • To determine the efficacy of a low dosage (0.15 mg) of intravitreal conbercept (IVC) for treating Zone II Stage 2/3+ retinopathy of prematurity (ROP).
  • To assess the safety and ocular outcomes of this low-dose IVC treatment in premature infants.

Main Methods:

  • Retrospective analysis of 38 eyes from 20 infants with Zone II Stage 2/3+ ROP treated with low-dose IVC (0.15 mg).
  • Treatment effectiveness was defined as complete regression of retinopathy and retinal vascularization to zone III.
  • Infant demographics included mean gestational age (GA) of 28.6 weeks, postmenstrual age (PMA) at treatment of 39.3 weeks, and birth weight (BW) of 1297.5 g.

Main Results:

  • Primary effectiveness was observed in 84.2% (32/38 eyes) with a single low-dose IVC injection.
  • Secondary effectiveness, requiring a second IVC injection, was noted in 15.8% (6/38 eyes).
  • Follow-up until 90 weeks PMA revealed no recurrence of plus disease or neovascularization, indicating sustained efficacy and safety.

Conclusions:

  • A low dosage of 0.15 mg intravitreal conbercept (IVC) is effective for treating Zone II Stage 2/3+ retinopathy of prematurity (ROP).
  • The treatment demonstrated a favorable safety profile with no adverse ocular outcomes during the follow-up period.
  • This low-dose IVC approach offers a potentially safer alternative for managing ROP in premature infants.

More Related Videos

Intravitreal Injections in the Ovine Eye03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.1K
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

9.4K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
806
Biological Effects of Radiation02:59

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
18.0K
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
312
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
246
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.5K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.2K